Original Article

You have full text access to this OnlineOpen article

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C

  1. Akinori Kasahara1,
  2. Norio Hayashi M.D.1,*,
  3. Kiyoshi Mochizuki1,
  4. Masahide Takayanagi1,
  5. Kentaro Yoshioka1,
  6. Shinichi Kakumu2,
  7. Akihiro Iijima1,
  8. Akihiko Urushihara1,
  9. Kendo Kiyosawa3,
  10. Michiari Okuda1,
  11. Keisuke Hino1,
  12. Kiwamu Okita4

Article first published online: 30 DEC 2003

DOI: 10.1002/hep.510270529

Issue

Hepatology

Hepatology

Volume 27, Issue 5, pages 1394–1402, May 1998

Additional Information

How to Cite

Kasahara, A., Hayashi, N., Mochizuki, K., Takayanagi, M., Yoshioka, K., Kakumu, S., Iijima, A., Urushihara, A., Kiyosawa, K., Okuda, M., Hino, K. and Okita, K. (1998), Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology, 27: 1394–1402. doi: 10.1002/hep.510270529

Author Information

  1. 1

    First Department of Medicine, Osaka University School of Medicine, Osaka, Japan

  2. 2

    Third Department of Medicine, Nagoya University School of Medicine, Nagoya, Japan

  3. 3

    Second Department of Medicine, Shinshu University School of Medicine, Matsumoto, Japan

  4. 4

    First Department of Medicine, Yamaguchi University School of Medicine, Ube, Japan

*First Department of Medicine, Osaka University School of Medicine, 2-2, Yamadaoka, Suita City, Osaka 565-0871, Japan. Fax: 81-6-879-3639

Publication History

  1. Issue published online: 30 DEC 2003
  2. Article first published online: 30 DEC 2003
  3. Manuscript Accepted: 2 DEC 1997
  4. Manuscript Received: 22 JUL 1997

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (112K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Vivek Kohli, Ashish Singhal, Lenzi Elliott, Sajid Jalil, Antiviral therapy for recurrent hepatitis C reduces recurrence of hepatocellular carcinoma following liver transplantation, Transplant International, 2012, 25, 2
    Direct Link:
  2. 2
    Dimitrios Stagos, Gregorios Amougias, Antonios Matakos, Argyris Spyrou, Aristides M. Tsatsakis, Dimitrios Kouretas, Chemoprevention of liver cancer by plant polyphenols, Food and Chemical Toxicology, 2012, 50, 6, 2155

    CrossRef

  3. 3
    Masaya Saito, Yasushi Seo, Yoshihiko Yano, Akira Miki, Yukiko Morinaga, Tomoo Itoh, Masaru Yoshida, Takeshi Azuma, Development of a hepatocellular carcinoma in a chronic hepatitis C patient 18 years after achieving a sustained virological response to interferon therapy: case report and literature review, Clinical Journal of Gastroenterology, 2012, 5, 2, 119

    CrossRef

  4. 4
    Yasuji Arase, Mariko Kobayashi, Fumitaka Suzuki, Yoshiyuki Suzuki, Yusuke Kawamura, Norio Akuta, Norihiro Imai, Masahiro Kobayashi, Hitomi Sezaki, Naoki Matsumoto, Satoshi Saito, Tetsuya Hosaka, Kenji Ikeda, Hiromitsu Kumada, Yuki Ohmoto, Kazuhisa Amakawa, Shiun Dong Hsieh, Kyoko Ogawa, Maho Tanabe, Hiroshi Tsuji, Tetsuro Kobayashi, Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients, Hepatology Research, 2012, 42, 3
    Direct Link:
  5. 5
    Eiji Kajiwara, Aritune Ooho, Naoki Yamashita, Effectiveness of biweekly low-dosage peginterferon treatment on the improvement of serum alanine aminotransferase and α-fetoprotein levels, Hepatology Research, 2012, 42, 3
    Direct Link:
  6. 6
    Hidenori Toyoda, Takashi Kumada, Incidence of hepatocellular carcinoma and response to interferon therapy in HCV-infected patients: effect of factors associated with the therapeutic response and incidence of HCC, Liver International, 2012, 32, 5
    Direct Link:
  7. 7
    Daisuke Maruoka, Fumio Imazeki, Makoto Arai, Tatsuo Kanda, Keiichi Fujiwara, Osamu Yokosuka, Long-term cohort study of chronic hepatitis C according to interferon efficacy, Journal of Gastroenterology and Hepatology, 2012, 27, 2
    Direct Link:
  8. 8
    Bruce R. Bacon, Omer Khalid, Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders, Liver International, 2012, 32,
    Direct Link:
  9. 9
    Manri Kawakami, Yasuhiro Umekawa, A female patient developing hepatocellular carcinoma 4.5 years after sustained virological response to interferon therapy for chronic hepatitis C: Comparison with cases of male patients, Kanzo, 2011, 52, 11, 722

    CrossRef

  10. 10
    E. Maillard, Épidémiologie, histoire naturelle et pathogenèse du carcinome hépatocellulaire, Cancer/Radiothérapie, 2011, 15, 1, 3

    CrossRef

  11. 11
    Yuko Nagaoki, Hiroshi Aikata, Daisuke Miyaki, Eisuke Murakami, Yoshimasa Hashimoto, Yoshio Katamura, Takahiro Azakami, Tomokazu Kawaoka, Shintaro Takaki, Akira Hiramatsu, Koji Waki, Michio Imamura, Yoshiiku Kawakami, Shoichi Takahashi, Kazuaki Chayama, Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy, Journal of Gastroenterology, 2011, 46, 6, 799

    CrossRef

  12. 12
    Yukio Osaki, Yoshihide Ueda, Hiroyuki Marusawa, Jun Nakajima, Toru Kimura, Ryuichi Kita, Hiroki Nishikawa, Sumio Saito, Shinichiro Henmi, Azusa Sakamoto, Yuji Eso, Tsutomu Chiba, Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study, Journal of Gastroenterology, 2011, 47, 4, 444

    CrossRef

  13. 13
    Hirokazu Miyatake, Yoshiyuki Kobayashi, Yoshiaki Iwasaki, Shin-ichiro Nakamura, Hideki Ohnishi, Kenji Kuwaki, Junichi Toshimori, Hiroaki Hagihara, Kazuhiro Nouso, Kazuhide Yamamoto, Effect of Previous Interferon Treatment on Outcome After Curative Treatment for Hepatitis C Virus-Related Hepatocellular Carcinoma, Digestive Diseases and Sciences, 2011, 57, 4, 1092

    CrossRef

  14. 14
    José Velosa, Fátima Serejo, Rui Marinho, Joana Nunes, Helena Glória, Eradication of Hepatitis C Virus Reduces the Risk of Hepatocellular Carcinoma in Patients with Compensated Cirrhosis, Digestive Diseases and Sciences, 2011, 56, 6, 1853

    CrossRef

  15. 15
    Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Kiyoshi Mochizuki, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Hiroyuki Fukui, Yoshiaki Inui, Taizo Hijioka, Masami Inada, Kazuhiro Kaytayama, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Michio Kato, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Tetsuo Takehara, Norio Hayashi, Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy, Journal of Hepatology, 2011, 54, 4, 604

    CrossRef

  16. 16
    Shinji Takashimizu, Sei-ichiro Kojima, Junko Nagata, Yasuhiro Nishizaki, Tatehiro Kagawa, Koichi Shiraishi, Tetsuya Mine, Jun-ichi Kaneko, Norihiro Kokudo, Norihito Watanabe, Intrahepatic cholangiocellular carcinoma and hepatocellular carcinoma developed after a 6-year sustained virological response to interferon therapy for chronic hepatitis C, Clinical Journal of Gastroenterology, 2011, 4, 3, 167

    CrossRef

  17. 17
    Masatoshi Kudo, Namiki Izumi, Norihiro Kokudo, Osamu Matsui, Michiie Sakamoto, Osamu Nakashima, Masamichi Kojiro, Masatoshi Makuuchi, Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version, Digestive Diseases, 2011, 29, 3, 339

    CrossRef

  18. 18
    Omer Khalid, Bruce R. Bacon, Management of the Treatment-Experienced Patient Infected with Hepatitis C Virus Genotype 1: Options and Considerations, Clinics in Liver Disease, 2011, 15, 3, 573

    CrossRef

  19. 19
    Helen S. Yee, Sue L. Currie, Kathryn Tortorice, Myrna Cozen, Hui Shen, Summer Chapman, Fran Cunningham, Alexander Monto, Retreatment of Hepatitis C with Consensus Interferon and Ribavirin After Nonresponse or Relapse to Pegylated Interferon and Ribavirin: A National VA Clinical Practice Study, Digestive Diseases and Sciences, 2011, 56, 8, 2439

    CrossRef

  20. 20
    Hiroshi Adachi, Katsuhisa Inamura, Toshiyuki Okamura, Tatsuho Sugimoto, The anti-viral effect and the influence on the values of ALT and AFP by low-dose PEG-IFNα2a treatment for prevention of cancer in patients with chronic hepatitis C, Kanzo, 2011, 52, 2, 94

    CrossRef

  21. 21
    Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Kiyoshi Mochizuki, Kazuho Imanaka, Akira Yamada, Masahide Oshita, Akira Kaneko, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Toshihiko Nagase, Yoshiaki Inui, Taizo Hijioka, Shinji Tamura, Harumasa Yoshihara, Eijiro Hayashi, Yasuharu Imai, Michio Kato, Atsushi Hosui, Takuya Miyagi, Yuichi Yoshida, Hisashi Ishida, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Tetsuo Takehara, Norio Hayashi, The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan, Journal of Gastroenterology, 2011, 46, 7, 944

    CrossRef

  22. 22
    Nobuyoshi Fukushima, Ryoko Kuromatsu, Teruko Arinaga-Hino, Eiji Ando, Akio Takata, Shuji Sumie, Masahito Nakano, Takumi Kawaguchi, Tatsuya Ide, Takuji Torimura, Michio Sata, Adipocytokine involvement in hepatocellular carcinoma after sustained response to interferon for chronic hepatitis C, Hepatology Research, 2010, 40, 9
    Direct Link:
  23. 23
    Kenji Ikeda, Masahiro Kobayashi, Yuya Seko, Norihiro Imai, Miharu Hirakawa, Yusuke Kawamura, Hitomi Sezaki, Tetsuya Hosaka, Norio Akuta, Satoshi Saitoh, Fumitaka Suzuki, Yoshiyuki Suzuki, Yasuji Arase, Hiromitsu Kumada, Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer, Hepatology Research, 2010, 40, 12
    Direct Link:
  24. 24
    Masakuni Tateyama, Hiroshi Yatsuhashi, Naota Taura, Yasuhide Motoyoshi, Shinya Nagaoka, Kenji Yanagi, Seigo Abiru, Koji Yano, Atsumasa Komori, Kiyoshi Migita, Minoru Nakamura, Hiroyasu Nagahama, Yutaka Sasaki, Yuzo Miyakawa, Hiromi Ishibashi, Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus, Journal of Gastroenterology, 2010, 46, 1, 92

    CrossRef

  25. 25
    Ryota Masuzaki, Haruhiko Yoshida, Masao Omata, Does chemotherapy prevent HCV-related hepatocellular carcinoma? Pros, Digestive and Liver Disease, 2010, 42, S281

    CrossRef

  26. 26
    Yoshito Tomimaru, Hiroaki Nagano, Hidetoshi Eguchi, Shogo Kobayashi, Shigeru Marubashi, Hiroshi Wada, Masahiro Tanemura, Koji Umeshita, Naoki Hiramatsu, Tetsuo Takehara, Yuichiro Doki, Masaki Mori, Effects of preceding interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma, Journal of Surgical Oncology, 2010, 102, 4
    Direct Link:
  27. 27
    Tetsuya Nishiura, Hideaki Watanabe, Koji Yano, Masahiro Ito, Seigo Abiru, Toshifumi Fujimoto, Atsumasa Komori, Hiroshi Yatsuhashi, Yojiro Matsuoka, Hiromi Ishibashi, Integrated fibrosis scoring by ultrasonography predicts the occurrence of hepatocellular carcinoma in patients with chronic hepatitis C virus infection, Journal of Medical Ultrasonics, 2010, 38, 1, 13

    CrossRef

  28. 28
    Timothy R. Morgan, Marc G. Ghany, Hae-Young Kim, Kristin K. Snow, Mitchell L. Shiffman, Jennifer L. De Santo, William M. Lee, Adrian M. Di Bisceglie, Herbert L. Bonkovsky, Jules L. Dienstag, Chihiro Morishima, Karen L. Lindsay, Anna S. F. Lok, Outcome of sustained virological responders with histologically advanced chronic hepatitis C, Hepatology, 2010, 52, 3
    Direct Link:
  29. 29
    Y. Imai, S. Tamura, H. Tanaka, N. Hiramatsu, S. Kiso, Y. Doi, M. Inada, T. Nagase, T. Kitada, K. Imanaka, K. Fukuda, T. Takehara, A. Kasahara, N. Hayashi, Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders, Journal of Viral Hepatitis, 2010, 17, 3
    Direct Link:
  30. 30
    Adrian M. Di Bisceglie, Alex S. Befeler, Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 2010,

    CrossRef

  31. 31
    Mika Kurokawa, Naoki Hiramatsu, Tsugiko Oze, Kiyoshi Mochizuki, Takayuki Yakushijin, Nao Kurashige, Yuko Inoue, Takumi Igura, Kazuho Imanaka, Akira Yamada, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Yoshiaki Inui, Taizo Hijioka, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Michio Kato, Shinichi Kiso, Tatsuya Kanto, Tetsuo Takehara, Akinori Kasahara, Norio Hayashi, Effect of interferon α-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis, Hepatology Research, 2009, 39, 5
    Direct Link:
  32. 32
    I. Itose, T. Kanto, N. Kakita, S. Takebe, M. Inoue, K. Higashitani, M. Miyazaki, H. Miyatake, M. Sakakibara, N. Hiramatsu, T. Takehara, A. Kasahara, N. Hayashi, Enhanced ability of regulatory T cells in chronic hepatitis C patients with persistently normal alanine aminotransferase levels than those with active hepatitis, Journal of Viral Hepatitis, 2009, 16, 12
    Direct Link:
  33. 33
    Takeji Umemura, Tetsuya Ichijo, Kaname Yoshizawa, Eiji Tanaka, Kendo Kiyosawa, Epidemiology of hepatocellular carcinoma in Japan, Journal of Gastroenterology, 2009, 44, S19, 102

    CrossRef

  34. 34
    Sara Raimondi, Savino Bruno, Mario U. Mondelli, Patrick Maisonneuve, Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: A meta-analysis, Journal of Hepatology, 2009, 50, 6, 1142

    CrossRef

  35. 35
    Birke Bartosch, Robert Thimme, Hubert E. Blum, Fabien Zoulim, Hepatitis C virus-induced hepatocarcinogenesis, Journal of Hepatology, 2009, 51, 4, 810

    CrossRef

  36. 36
    Andrew Aronsohn, Nancy Reau, Long-term Outcomes After Treatment With Interferon and Ribavirin in HCV Patients, Journal of Clinical Gastroenterology, 2009, 43, 7, 661

    CrossRef

  37. 37
    Kenji Ikeda, Yasuji Arase, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Tetsuya Hosaka, Norio Akuta, Masahiro Kobayashi, Satoshi Saitoh, Fumitaka Suzuki, Yoshiyuki Suzuki, Hiromitsu Kumada, Necessities of Interferon Therapy in Elderly Patients with Chronic Hepatitis C, The American Journal of Medicine, 2009, 122, 5, 479

    CrossRef

  38. 38
    T. Oze, N. Hiramatsu, T. Yakushijin, M. Kurokawa, T. Igura, K. Mochizuki, K. Imanaka, A. Yamada, M. Oshita, H. Hagiwara, E. Mita, T. Ito, Y. Inui, T. Hijioka, S. Tamura, H. Yoshihara, E. Hayashi, A. Inoue, Y. Imai, M. Kato, Y. Yoshida, T. Tatsumi, K. Ohkawa, S. Kiso, T. Kanto, A. Kasahara, T. Takehara, N. Hayashi, Pegylated interferon alpha-2b (Peg-IFN α-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α-2b plus ribavirin, Journal of Viral Hepatitis, 2009, 16, 8
    Direct Link:
  39. 39
    Shoji Kubo, Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapy, Clinical Journal of Gastroenterology, 2009, 2, 2, 65

    CrossRef

  40. 40
    Yoshiyuki Ueno, Jose D Sollano, Geoffrey C Farrell, Prevention of hepatocellular carcinoma complicating chronic hepatitis C, Journal of Gastroenterology and Hepatology, 2009, 24, 4
    Direct Link:
  41. 41
    Hui-Hui Tan, Thomas D. Schiano, Treatment of hepatitis C in the potential liver transplant recipient, Current Hepatitis Reports, 2009, 8, 2, 81

    CrossRef

  42. 42
    Makoto Chuma, Shuhei Hige, Mitsuru Nakanishi, Koji Ogawa, Mitsuteru Natsuizaka, Yoichi Yamamoto, Masahiro Asaka, 8-Hydroxy-2′-deoxy-guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection, Journal of Gastroenterology and Hepatology, 2008, 23, 9
    Direct Link:
  43. 43
    Chiharu Shima, Akira Yamada, Mako Tsubosaka, Motoko Sakurai, Kouji Nakatani, Kazuo Kinoshita, Osamu Kishida, Takashi Fujimoto, Yuzo Minami, A case of chronic hepatitis C with sustained virological response by an intermittent use of low dose pegylated interferon, Kanzo, 2008, 49, 10, 470

    CrossRef

  44. 44
    Daiki Miki, Hiroshi Aikata, Kiminori Uka, Hiromi Saneto, Tomokazu Kawaoka, Takahiro Azakami, Shintaro Takaki, Soo Cheol Jeong, Michio Imamura, Yoshiiku Kawakami, Shoichi Takahashi, Toshiyuki Itamoto, Toshimasa Asahara, Koji Arihiro, Kazuaki Chayama, Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma, Journal of Gastroenterology, 2008, 43, 7, 550

    CrossRef

  45. 45
    Carroll B. Leevy, Consensus Interferon and Ribavirin in Patients with Chronic Hepatitis C Who Were Nonresponders to Pegylated Interferon alfa-2b and Ribavirin, Digestive Diseases and Sciences, 2008, 53, 7, 1961

    CrossRef

  46. 46
    Naoki Hiramatsu, Nao Kurashige, Tsugiko Oze, Tetsuo Takehara, Shinji Tamura, Akinori Kasahara, Masahide Oshita, Kazuhiro Katayama, Harumasa Yoshihara, Yasuharu Imai, Michio Kato, Sumio Kawata, Hirohito Tsubouchi, Hiromitsu Kumada, Takeshi Okanoue, Shinichi Kakumu, Norio Hayashi, Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C, Hepatology Research, 2008, 38, 1
    Direct Link:
  47. 47
    Takeshi Okanoue, Yoshito Itoh, Masahito Minami, Hiroaki Hashimoto, Kohichiro Yasui, Hiroshi Yotsuyanagi, Tetsuo Takehara, Takashi Kumada, Eiji Tanaka, Shuhei Nishiguchi, Namiki Izumi, Michio Sata, Morikazu Onji, Gotaro Yamada, Kiwamu Okita, Hiromitsu Kumada, Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts, Hepatology Research, 2008, 38, 1
    Direct Link:
  48. 48
    Miharu Hirakawa, Kenji Ikeda, Yasuji Arase, Yusuke Kawamura, Hiromi Yatsuji, Tetsuya Hosaka, Hitomi Sezaki, Norio Akuta, Masahiro Kobayashi, Satoshi Saitoh, Fumitaka Suzuki, Yoshiyuki Suzuki, Hiromitsu Kumada, Hepatocarcinogenesis Following HCV RNA Eradication by Interferon in Chronic Hepatitis Patients, Internal Medicine, 2008, 47, 19, 1637

    CrossRef

  49. 49
    Ranka Vukotic, Annagiulia Gramenzi, Giovanni Vitale, Carmela Cursaro, Carla Serra, Maurizio Biselli, Alessandra Scuteri, Pietro Andreone, Mauro Bernardi, Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin, Liver International, 2008, 28, 3
    Direct Link:
  50. 50
    T.-M. Scherzer, K. R. Reddy, F. Wrba, H. Hofer, K. Staufer, P. Steindl-Munda, A. Gangl, P. Ferenci, Hepatocellular carcinoma in long-term sustained virological responders following antiviral combination therapy for chronic hepatitis C, Journal of Viral Hepatitis, 2008, 15, 9
    Direct Link:
  51. 51
    Masahiro Kobayashi, Kenji Ikeda, Yasuji Arase, Yoshiyuki Suzuki, Fumitaka Suzuki, Norio Akuta, Tetsuya Hosaka, Naoya Murashima, Satoshi Saitoh, Takashi Someya, Akihito Tsubota, Hiromitsu Kumada, Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus, Journal of Gastroenterology, 2008, 43, 1, 63

    CrossRef

  52. 52
    Mitsuharu Hanada, Akemi Baba, Yasuyuki Tsutsumishita, Toshihiro Noguchi, Takashi Yamaoka, Nobuyoshi Chiba, Fumio Nishikaku, Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis, Cancer Chemotherapy and Pharmacology, 2008, 64, 3, 473

    CrossRef

  53. 53
    Yoshihide Ueda, Yasutsugu Takada, Hironori Haga, Motoshige Nabeshima, Hiroyuki Marusawa, Takashi Ito, Hiroto Egawa, Koichi Tanaka, Shinji Uemoto, Tsutomu Chiba, Limited Benefit of Biochemical Response to Combination Therapy for Patients With Recurrent Hepatitis C After Living-Donor Liver Transplantation, Transplantation, 2008, 85, 6, 855

    CrossRef

  54. 54
    Haruaki Shirakawa, Akihiro Matsumoto, Satoru Joshita, Michiharu Komatsu, Naoki Tanaka, Takeji Umemura, Tetsuya Ichijo, Kaname Yoshizawa, Kendo Kiyosawa, Eiji Tanaka, Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors, Hepatology, 2008, 48, 6
    Direct Link:
  55. 55
    Takahiro Uenishi, Shuhei Nishiguchi, Shogo Tanaka, Takatsugu Yamamoto, Shigekazu Takemura, Shoji Kubo, Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma, Journal of Surgical Oncology, 2008, 98, 5
    Direct Link:
  56. 56
    Shoji Kubo, Shigekazu Takemura, Takahiro Uenishi, Takatsugu Yamamoto, Kazuki Ohba, Masao Ogawa, Seikan Hai, Tsuyoshi Ichikawa, Shintaro Kodai, Hiroji Shinkawa, Hiromu Tanaka, Second Hepatic Resection for Recurrent Hepatocellular Carcinoma in Patients with Chronic Hepatitis C, World Journal of Surgery, 2008, 32, 4, 632

    CrossRef

  57. 57
    S. Kobayashi, T. Takeda, M. Enomoto, A. Tamori, N. Kawada, D. Habu, H. Sakaguchi, T. Kuroda, K. Kioka, S. R. Kim, T. Kanno, T. Ueda, M. Hirano, S. Fujimoto, H. Jomura, S. Nishiguchi, S. Seki, Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients, Liver International, 2007, 27, 2
    Direct Link:
  58. 58
    Eiko Hasegawa, Masahiro Kobayashi, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Tetsuya Hosaka, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2, Hepatology Research, 2007, 37, 10
    Direct Link:
  59. 59
    Takeji Umemura, Kendo Kiyosawa, Epidemiology of hepatocellular carcinoma in Japan, Hepatology Research, 2007, 37,
    Direct Link:
  60. 60
    Hitomi Sezaki, Fumitaka Suzuki, Yusuke Kawamura, Hiromi Yatsuji, Tetsuya Hosaka, Norio Akuta, Masahiro Kobayashi, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load, Hepatology Research, 2007, 37, 10
    Direct Link:
  61. 61
    Hiroaki Okuda, Hepatocellular carcinoma development in cirrhosis, Best Practice & Research Clinical Gastroenterology, 2007, 21, 1, 161

    CrossRef

  62. 62
    Mitsuhiko Moriyama, Hiroshi Matsumura, Shu Oshiro, Hitomi Nakamura, Yasuo Arakawa, Kazushige Nirei, Hiroshi Aoki, Hiroaki Yamagami, Miki Kaneko, Naohide Tanaka, Yasuyuki Arakawa, Interferon Therapy Improves the Irregular Regeneration of Hepatocytes in Liver in Patients with C-Viral Chronic Hepatitis and Liver Cirrhosis, Intervirology, 2007, 50, 2, 138

    CrossRef

  63. 63
    Yasuji Arase, Kenji Ikeda, Fumitaka Suzuki, Yoshiyuki Suzuki, Masahiro Kobayashi, Norio Akuta, Tetsuya Hosaka, Hitomi Sezaki, Hiromi Yatsuji, Yusuke Kawamura, Mariko Kobayashi, Hiromitsu Kumada, Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection, Journal of Medical Virology, 2007, 79, 10
    Direct Link:
  64. 64
    Hideaki Taniguchi, Yoshiaki Iwasaki, Akira Takahashi, Hiroyuki Shimomura, Akio Moriya, Piao Cheng Yu, Fumi Umeoka, Shin-ichi Fujioka, Norio Koide, Yasushi Shiratori, Intrahepatic mRNA Levels of Type I Interferon Receptor and Interferon-Stimulated Genes in Genotype 1b Chronic Hepatitis C, Intervirology, 2007, 50, 1, 32

    CrossRef

  65. 65
    Soo R. Kim, Is long-term interferon monotherapy welcome news for older patients with chronic hepatitis C genotype 1?, Hepatology Research, 2007, 37, 7
    Direct Link:
  66. 66
    Yasuji Arase, Kenji Ikeda, Fumitaka Suzuki, Yoshiyuki Suzuki, Satoshi Saitoh, Masahiro Kobayashi, Norio Akuta, Takashi Someya, Rikako Koyama, Tetsuya Hosaka, Hitomi Sezaki, Mariko Kobayashi, Hiromitsu Kumada, Long-Term Outcome after Interferon Therapy in Elderly Patients with Chronic Hepatitis C, Intervirology, 2007, 50, 1, 16

    CrossRef

  67. 67
    Akihiro Tamori, Daiki Habu, Susumu Shiomi, Shoji Kubo, Shuhei Nishiguchi, Potential role of vitamin K2 as a chemopreventive agent against hepatocellular carcinoma, Hepatology Research, 2007, 37,
    Direct Link:
  68. 68
    Toru Ishikawa, Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients, Journal of Microwave Surgery, 2007, 25, 63

    CrossRef

  69. 69
    Yasuji Arase, Kenji Ikeda, Yoshiyuki Suzuki, Masahiro Kobayashi, Fumitaka Suzuki, Norio Akuta, Hitomi Sezaki, Tetsuya Hosaka, Hiromi Yatsuji, Yusuke Kawamura, Mariko Kobayashi, Hiromitsu Kumada, Serum KL-6 Level is Elevated in Chronic Hepatitis C Patients with Combination Therapy of Pegylated Interferon and Ribavirin, Internal Medicine, 2007, 46, 15, 1155

    CrossRef

  70. 70
    Isao Hidaka, Keisuke Hino, Masaaki Korenaga, Toshikazu Gondo, Sohji Nishina, Miye Ando, Michiari Okuda, Isao Sakaida, Stronger Neo-Minophagen C™, a glycyrrhizin-containing preparation, protects liver against carbon tetrachloride-induced oxidative stress in transgenic mice expressing the hepatitis C virus polyprotein, Liver International, 2007, 27, 6
    Direct Link:
  71. 71
    Shoji Kubo, Hiromu Tanaka, Shigekazu Takemura, Satoshi Yamamoto, Seikan Hai, Tsuyoshi Ichikawa, Shintaro Kodai, Hiroji Shinkawa, Taichi Shuto, Kazuhiro Hirohashi, Surgical Treatment for Hepatocellular Carcinoma Detected After Successful Interferon Therapy, Surgery Today, 2007, 37, 4, 285

    CrossRef

  72. 72
    Savino Bruno, Tommaso Stroffolini, Massimo Colombo, Simona Bollani, Luisa Benvegnù, Giuseppe Mazzella, Antonio Ascione, Teresa Santantonio, Felice Piccinino, Pietro Andreone, Alessandra Mangia, Giovanni B. Gaeta, Marcello Persico, Stefano Fagiuoli, Piero L. Almasio, Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: A retrospective study, Hepatology, 2007, 45, 3
    Direct Link:
  73. 73
    Youichi Kawano, Kaku Egami, Koji Sasajima, Masayuki Miyamoto, Tadashi Yokoyama, Shotaro Maeda, Hiroshi Yoshida, Yasuhiro Mamada, Nobuhiko Taniai, Takashi Tajiri, Kanzo, 2007, 48, 2, 48

    CrossRef

  74. 74
    A. ZIMMERMANN, Surgery of the Liver, Biliary Tract and Pancreas, 2007,

    CrossRef

  75. 75
    HIDENORI TOYODA, TAKASHI KUMADA, ‘YES, NOW YOU ARE FREE FROM CHRONIC HCV INFECTION, BUT . . .’, Journal of Gastroenterology and Hepatology, 2006, 21, 1
    Direct Link:
  76. 76
    Kenji Ikeda, Yasuji Arase, Masahiro Kobayashi, Satoshi Saitoh, Takashi Someya, Tetsuya Hosaka, Hitomi Sezaki, Norio Akuta, Yoshiyuki Suzuki, Fumitaka Suzuki, Hiromitsu Kumada, A Long-Term Glycyrrhizin Injection Therapy Reduces Hepatocellular Carcinogenesis Rate in Patients with Interferon-Resistant Active Chronic Hepatitis C: A Cohort Study of 1249 Patients, Digestive Diseases and Sciences, 2006, 51, 3, 603

    CrossRef

  77. 77
    Masahiko Kaito, Shinichiro Horiike, Hideaki Tanaka, Naoki Fujita, Yukihiko Adachi, Accumulation of 8-n itroguanine in the liver of chronic hepatitis C patients without sustained virological response after completion of interferon therapy, Journal of Gastroenterology, 2006, 41, 7, 713

    CrossRef

  78. 78
    Kenji Ikeda, Yasuji Arase, Satoshi Saitoh, Masahiro Kobayashi, Takashi Someya, Tetsuya Hosaka, Hitomi Sezaki, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Hiromitsu Kumada, Anticarcinogenic Impact of Interferon on Patients with Chronic Hepatitis C: A Large-Scale Long-Term Study in a Single Center, Intervirology, 2006, 49, 1-2, 82

    CrossRef

  79. 79
    Norio Hayashi, Tetsuo Takehara, Antiviral therapy for chronic hepatitis C: past, present, and future, Journal of Gastroenterology, 2006, 41, 1, 17

    CrossRef

  80. 80
    Hans Orlent, Bettina E. Hansen, Marc Willems, Johannes T. Brouwer, Roman Huber, Gerd A. Kullak-Ublick, Guido Gerken, Stefan Zeuzem, Frederik Nevens, Wanda C.M. Tielemans, Pieter E. Zondervan, Martin Lagging, Johan Westin, Solko W. Schalm, Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: A randomized phase II trial, Journal of Hepatology, 2006, 45, 4, 539

    CrossRef

  81. 81
    Kiwamu Okita, Clinical Aspects of Hepatocellular Carcinoma in Japan, Internal Medicine, 2006, 45, 5, 229

    CrossRef

  82. 82
    MASAFUMI IKEDA, SHIGETOSHI FUJIYAMA, MOTOHIKO TANAKA, MICHIO SATA, TATSUYA IDE, HIROSHI YATSUHASHI, HIROSHI WATANABE, Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C, Journal of Gastroenterology and Hepatology, 2006, 21, 1
    Direct Link:
  83. 83
    Masahiro Kobayashi, Kenji Ikeda, Tetsuya Hosaka, Hitomi Sezaki, Takashi Someya, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Hiromitsu Kumada, Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis, Cancer, 2006, 106, 3
    Direct Link:
  84. 84
    Tsugiko Oze, Naoki Hiramatsu, Nao Kurashige, Natsuko Tsuda, Takayuki Yakushijin, Tatsuya Kanto, Tetsuo Takehara, Akinori Kasahara, Michio Kato, Harumasa Yoshihara, Kazuhiro Katayama, Shinji Kubota, Taizo Hijioka, Kazunobu Ishibashi, Masahide Oshita, Hideki Hagiwara, Yoshimichi Haruna, Eiji Mita, Shinji Tamura, Norio Hayashi, Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C, Journal of Gastroenterology, 2006, 41, 9, 862

    CrossRef

  85. 85
    Kiminori Uka, Fumitaka Suzuki, Norio Akuta, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Takashi Someya, Masahiro Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection, Journal of Gastroenterology, 2006, 41, 5, 470

    CrossRef

  86. 86
    Rikako Koyama, Yasuji Arase, Kenji Ikeda, Fumitaka Suzuki, Yoshiyuki Suzuki, Satoshi Saitoh, Masahiro Kobayashi, Norio Akuta, Takashi Someya, Tetsuya Hosaka, Hitomi Sezaki, Mariko Kobayashi, Hiromitsu Kumada, Efficacy of Interferon Therapy in Elderly Patients with Chronic Hepatitis C, Intervirology, 2006, 49, 3, 121

    CrossRef

  87. 87
    John B Wong, Hepatitis C, PharmacoEconomics, 2006, 24, 7, 661

    CrossRef

  88. 88
    Youko Idobe-Fujii, Nagako Ogi, Keiko Hosho, Masahiko Koda, Yoshikazu Murawaki, Yasushi Horie, Hepatocellular carcinoma with sarcomatous change arising after eradication of HCV via interferon therapy, Clinical Imaging, 2006, 30, 6, 416

    CrossRef

  89. 89
    Hui Xu, Xuan Li, Zheng-han Yang, Jing-xia Xie, In Vivo 1H MR Spectroscopy in the Evaluation of the Serial Development of Hepatocarcinogenesis in an Experimental Rat Model, Academic Radiology, 2006, 13, 12, 1532

    CrossRef

  90. 90
    C.-H. Hung, C.-M. Lee, S.-N. Lu, J.-H. Wang, T.-H. Hu, H.-D. Tung, C.-H. Chen, W.-J. Chen, C.-S. Changchien, Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis, Journal of Viral Hepatitis, 2006, 13, 6
    Direct Link:
  91. 91
    Kiwamu Okita, Management of hepatocellular carcinoma in Japan, Journal of Gastroenterology, 2006, 41, 2, 100

    CrossRef

  92. 92
    Masahiro Kobayashi, Kenji Ikeda, Tetsuya Hosaka, Hitomi Sezaki, Takashi Someya, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Yuzo Miyakawa, Hiromitsu Kumada, Natural history of compensated cirrhosis in the Child-Pugh class a compared between 490 patients with hepatitis C and 167 with B virus infections, Journal of Medical Virology, 2006, 78, 4
    Direct Link:
  93. 93
    Liana Fraenkel, Sarah McGraw, Suchat Wongcharatrawee, Guadalupe Garcia-Tsao, Patients’ experiences related to anti-viral treatment for hepatitis C, Patient Education and Counseling, 2006, 62, 1, 148

    CrossRef

  94. 94
    Sergey Akimov, Oluwatoyin M Adeyemi, Peginterferon-α2ain the treatment of chronic hepatitis C, Future Virology, 2006, 1, 6, 689

    CrossRef

  95. 95
    Keiichi Fujiwara, Osamu Yokosuka, Fumihiko Komine, Mitsuhiko Moriyama, Naoya Kato, Haruhiko Yoshida, Naohide Tanaka, Fumio Imazeki, Yasushi Shiratori, Yasuyuki Arakawa, Masao Omata, Twenty-four weeks of interferon α-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1, Liver International, 2006, 26, 5
    Direct Link:
  96. 96
    Takeshi Okanoue, Akiko Makiyama, Mika Nakayama, Yoshio Sumida, Hironori Mitsuyoshi, Tomoki Nakajima, Kohichiroh Yasui, Masahito Minami, Yoshito Itoh, A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase, Journal of Hepatology, 2005, 43, 4, 599

    CrossRef

  97. 97
    Shinichiro Horiike, Shosuke Kawanishi, Masahiko Kaito, Ning Ma, Hideaki Tanaka, Naoki Fujita, Motoh Iwasa, Yoshinao Kobayashi, Yusuke Hiraku, Shinji Oikawa, Mariko Murata, Jinyan Wang, Reiji Semba, Shozo Watanabe, Yukihiko Adachi, Accumulation of 8-nitroguanine in the liver of patients with chronic hepatitis C, Journal of Hepatology, 2005, 43, 3, 403

    CrossRef

  98. 98
    H. Toyoda, T. Kumada, S. Kiriyama, Y. Sone, M. Tanikawa, Y. Hisanaga, T. Kuzuya, T. Honda, K. Hayashi, I. Nakano, Y. Katano, H. Goto, Changes in Hepatitis C Virus (HCV) Antibody Status in Patients with Chronic Hepatitis C after Eradication of HCV Infection by Interferon Therapy, Clinical Infectious Diseases, 2005, 40, 6, e49

    CrossRef

  99. 99
    Mitsuhiko Moriyama, Hiroshi Matsumura, Hiroshi Aoki, Toshihiro Shimizu, Hiroaki Yamagami, Atsuo Shioda, Miki Kaneko, Iori Goto, Naohide Tanaka, Yasuyuki Arakawa, Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy, Liver International, 2005, 25, 1
    Direct Link:
  100. 100
    Namiki Izumi, Asahina Yasuhiro, Masayuki Kurosaki, Yuko Onuki, Yuki Nishimura, Kazunari Inoue, Ken Ueda, Kaoru Tsuchiya, Hiroyuki Nakanishi, Masakatsu Uchihara, Shozo Miyake, Development of Hepatocellular Carcinoma after Interferon Therapy in Chronic Hepatitis C, Intervirology, 2005, 48, 1, 59

    CrossRef

  101. 101
    Kazuya Matsumoto, Jun-ichi Okano, Yoshikazu Murawaki, Differential effects of interferon alpha-2b and beta on the signaling pathways in human liver cancer cells, Journal of Gastroenterology, 2005, 40, 7, 722

    CrossRef

  102. 102
    TOSHIO ARIYASU, TAKESHI TANAKA, NOBORU FUJIOKA, YOSHIAKI YANAI, SHIGETO YAMAMOTO, HIROSHI YAMAUCHI, HAKUO IKEGAMI, MASAO IKEDA, MASASHI KURIMOTO, EFFECTS OF INTERFERON-ALPHA SUBTYPES ON THE TH1/TH2 BALANCE IN PERIPHERAL BLOOD MONONUCLEAR CELLS FROM PATIENTS WITH HEPATITIS VIRUS INFECTION–ASSOCIATED LIVER DISORDERS, In Vitro Cellular & Developmental Biology - Animal, 2005, 41, 1, 50

    CrossRef

  103. 103
    Izumi Hasegawa, Etsuro Orito, Yasuhito Tanaka, Noboru Hirashima, Kenji Sakakibara, Mayumi Sakurai, Seiji Suzuki, Fuminaka Sugauchi, Tomoyoshi Ohno, Ryuzo Ueda, Masashi Mizokami, Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-α therapy for patients with chronic hepatitis C, Liver International, 2005, 25, 2
    Direct Link:
  104. 104
    M. F. Donato, C. Degott, E. Arosio, M. Martinot, V. Monti, A. Morabito, P. Marcellin, M. Colombo, Interferon-α suppresses liver cell proliferation in patients with chronic hepatitis C virus infection, Journal of Viral Hepatitis, 2005, 12, 5
    Direct Link:
  105. 105
    Ke Ih Kim, Noriko Sasase, Miyuki Taniguchi, Keiji Mita, Soo Ryang Kim, Kazuhiko Tanaka, Yoshitake Hayashi, Prediction of Efficacy of Interferon Treatment of Chronic Hepatitis C and Occurrence of HCC after Interferon Treatment by a New Classification, Intervirology, 2005, 48, 1, 52

    CrossRef

  106. 106
    Kazuhiro Hayashida, Akito Daiba, Akito Sakai, Takeshi Tanaka, Kyosuke Kaji, Niro Inaba, Satoshi Ando, Naoki Kajiyama, Hiroshi Terasaki, Aki Abe, Masanori Ogasawara, Michinori Kohara, Mine Harada, Takeshi Okanoue, Satoru Ito, Shuichi Kaneko, Pretreatment Prediction of Interferon-Alfa Efficacy in Chronic Hepatitis C Patients, Clinical Gastroenterology and Hepatology, 2005, 3, 12, 1253

    CrossRef

  107. 107
    Michael C. KEW, Prevention of hepatocellular carcinoma, HPB, 2005, 7, 1
    Direct Link:
  108. 108
    Antonio Craxì, Calogero Cammà, Prevention of Hepatocellular Carcinoma, Clinics in Liver Disease, 2005, 9, 2, 329

    CrossRef

  109. 109
    Koji Takai, Masataka Okuno, Ichiro Yasuda, Rie Matsushima-Nishiwaki, Takahiro Uematsu, Hisashi Tsurumi, Yoshimune Shiratori, Yasutoshi Muto, Hisataka Moriwaki, Prevention of Second Primary Tumors by an Acyclic Retinoid in Patients with Hepatocellular Carcinoma, Intervirology, 2005, 48, 1, 39

    CrossRef

  110. 110
    HAJIME TOKITA, HIDEO FUKUI, AKIHISA TANAKA, HIROSHI KAMITSUKASA, MICHIYASU YAGURA, HIDEHARU HARADA, HIROAKI OKAMOTO, Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy, Journal of Gastroenterology and Hepatology, 2005, 20, 5
    Direct Link:
  111. 111
    Lihua Wang, Marc S. Levin, Suppression of FGF signaling: A putative mechanism for the chemopreventive effects of acyclic retinoid in hepatocellular carcinoma, Gastroenterology, 2005, 128, 1, 228

    CrossRef

  112. 112
    Anne M. Larson, The epidemiology of hepatocellular carcinoma in hcv, Current Hepatitis Reports, 2005, 4, 4, 145

    CrossRef

  113. 113
    Akiko Makiyama, Yoshito Itoh, Akinori Kasahara, Yasuharu Imai, Sumio Kawata, Kentaro Yoshioka, Hirohito Tsubouchi, Kendo Kiyosawa, Shinichi Kakumu, Kiwamu Okita, Norio Hayashi, Takeshi Okanoue, Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy, Cancer, 2004, 101, 7
    Direct Link:
  114. 114
    S.-M. Lin, D.-I. Tai, R.-N. Chien, I.-S. Sheen, C.-M. Chu, Y.-F. Liaw, Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B, Journal of Viral Hepatitis, 2004, 11, 4
    Direct Link:
  115. 115
    Shirley A. Coverdale, Mahbub H. Khan, Karen Byth, Rita Lin, Martin Weltman, Jacob George, Dev Samarasinghe, Christopher Liddle, James G. Kench, Evelyn Crewe, Geoffrey C. Farrell, Effects of Interferon Treatment Response on Liver Complications of Chronic Hepatitis C: 9-year Follow-Up Study, The American Journal of Gastroenterology, 2004, 99, 4, 636

    CrossRef

  116. 116
    Kendo Kiyosawa, Takeji Umemura, Tetsuya Ichijo, Akihiro Matsumoto, Kaname Yoshizawa, Amal Gad, Eiji Tanaka, Hepatocellular carcinoma: Recent trends in Japan, Gastroenterology, 2004, 127, 5, S17

    CrossRef

  117. 117
    Osamu Yokosuka, Shosuke Iwama, Noriaki Suzuki, Motohide Takashi, Yasuo Hirai, Katsuo Uchiumi, Michio Kimura, Nobuaki Gotou, Shinichi Hino, Akira Hayasaka, Tatsuo Kanda, Shigenobu Kawai, Kenichi Fukai, Fumio Imazeki, Hiromitsu Saisho, High Sustained Virologic Response Rate after Interferon Monotherapy in Japanese Hepatitis C Patients with a Low HCV RNA Titer and/or HCV Genotype 2, Intervirology, 2004, 47, 6, 328

    CrossRef

  118. 118
    Noboru FUJIOKA, Takeshi TANAKA, Toshio ARIYASU, Yoshiaki YANAI, Shigeto YAMAMOTO, Hiroshi YAMAUCHI, Hakuo IKEGAMI, Masao IKEDA, Kunzo ORITA, Masashi KURIMOTO, In vitro effects of interferon-alpha subtypes on the Th1/Th2 balance in the peripheral blood mononuclear cells from patients with hepatitis C virus infection, Biomedical Research, 2004, 25, 2, 75

    CrossRef

  119. 119
    A. Kasahara, H. Tanaka, T. Okanoue, Y. Imai, H. Tsubouchi, K. Yoshioka, S. Kawata, E. Tanaka, K. Hino, K. Hayashi, S. Tamura, Y. Itoh, K. Kiyosawa, S. Kakumu, K. Okita, N. Hayashi, Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death, Journal of Viral Hepatitis, 2004, 11, 2
    Direct Link:
  120. 120
    Linda L Wong, Naoky Tsai, Whitney Limm, Livingston Wong, Liver transplant for hepatocellular cancer: a treatment for the select few, Clinical Transplantation, 2004, 18, 2
    Direct Link:
  121. 121
    Brett D. Kalmowitz, Nezam H. Afdhal, Maintenance therapies for hepatitis C, Current Hepatitis Reports, 2004, 3, 1, 23

    CrossRef

  122. 122
    Makoto ARIMA, Hideo TERAO, Kenji KASHIMA, Tsuyoshi ARITA, Masaru NASU, Akira NISHIZONO, Regression of Liver Fibrosis in Cases of Chronic Liver Disease Type C: Quantitative Evaluation by Using Computed Image Analysis, Internal Medicine, 2004, 43, 10, 902

    CrossRef

  123. 123
    Yoshiaki Iwasaki, Kouichi Takaguchi, Hiroshi Ikeda, Yasuhiro Makino, Yasuyuki Araki, Masaharu Ando, Haruhiko Kobashi, Toshitsugu Kobatake, Ryoji Tanaka, Minoru Tomita, Tomonori Senoh, Mitsuhiko Kawaguchi, Toshinari Shimoe, Koji Manabe, Keiji Kita, Junnosuke Shimamura, Kohsaku Sakaguchi, Yasushi Shiratori, Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy, Liver International, 2004, 24, 6
    Direct Link:
  124. 124
    Hideyuki Nomura, Suketo Sou, Hironori Tanimoto, Takashi Nagahama, Yoichi Kimura, Jun Hayashi, Hiromi Ishibashi, Seizaburo Kashiwagi, Short-term interferon-alfa therapy for acute hepatitis C: A randomized controlled trial, Hepatology, 2004, 39, 5
    Direct Link:
  125. 125
    Hidenori Toyoda, Takashi Kumada, Kazuhiko Hayashi, Takashi Honda, Kiyoshi Morita, Daisaku Nishimura, Kazumi Imada, Masami Imoto, Yuji Horiguchi, Hiroshi Nakano, Isao Nakano, Yoshihide Fukuda, Characteristics and prognosis of hepatocellular carcinoma detected in sustained responders to interferon therapy for chronic hepatitis C, Cancer Detection and Prevention, 2003, 27, 6, 498

    CrossRef

  126. 126
    SEIJI SUZUKI, YUTAKA KONDO, NOBORU HIRASHIMA, HIDEAKI KATO, FUMINAKA SUGAUCHI, YASUHITO TANAKA, ETSURO ORITO, YING YANG, YU SHEN, KENJI SAKAKIBARA, RYUZO UEDA, MASASHI MIZOKAMI, Evaluation of loss of heterozygosity before and after interferon therapy in patients with hepatitis C virus infection who developed hepatocellular carcinoma during follow up, Journal of Gastroenterology and Hepatology, 2003, 18, 12
    Direct Link:
  127. 127
    TAKESHI OKANOUE, YOSHITO ITOH, Hepatocellular carcinoma in sustained responders of interferon-treated chronic hepatitis C, Journal of Gastroenterology and Hepatology, 2003, 18, 2
    Direct Link:
  128. 128
    Ichiro Shimizu, Impact of oestrogens on the progression of liver disease, Liver International, 2003, 23, 1
    Direct Link:
  129. 129
    E. Tabor, Interferon for preventing and treating hepatocellular carcinoma associated with the hepatitis B and C viruses, Digestive and Liver Disease, 2003, 35, 5, 297

    CrossRef

  130. 130
    Takashi Horie, Isao Sakaida, Fumihiko Yokoya, Megumi Nakajo, Ichiro Sonaka, Kiwamu Okita, l-Cysteine administration prevents liver fibrosis by suppressing hepatic stellate cell proliferation and activation, Biochemical and Biophysical Research Communications, 2003, 305, 1, 94

    CrossRef

  131. 131
    Hiroshi Imamura, Yutaka Matsuyama, Eiji Tanaka, Takao Ohkubo, Kiyoshi Hasegawa, Shinichi Miyagawa, Yasuhiko Sugawara, Masami Minagawa, Tadatoshi Takayama, Seiji Kawasaki, Masatoshi Makuuchi, Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy, Journal of Hepatology, 2003, 38, 2, 200

    CrossRef

  132. 132
    Luigi Bolondi, Screening for hepatocellular carcinoma in cirrhosis, Journal of Hepatology, 2003, 39, 6, 1076

    CrossRef

  133. 133
    Kenta Suzuki, Shogo Ohkoshi, Masahiko Yano, Takafumi Ichida, Mitsuhiro Takimoto, Akira Naitoh, Shigeki Mori, Kojiro Hata, Kentaro Igarashi, Hidenori Hara, Hironobu Ohta, Kenji Soga, Toshiaki Watanabe, Tomoteru Kamimura, Yutaka Aoyagi, Sustained biochemical remission after interferon treatment may closely be related to the end of treatment biochemical response and associated with a lower incidence of hepatocarcinogenesis, Liver International, 2003, 23, 3
    Direct Link:
  134. 134
    Masaru Enomoto, Shuhei Nishiguchi, Susumu Shiomi, Motoharu Tanaka, Tadashi Yokogawa, Katsuhiko Fukuda, Tadashi Ueda, Akihiro Tamori, Daiki Habu, Tadashi Takeda, Yoshihisa Yano, Shuzo Otani, Changes in serum levels of hepatitis C virus genotype 1b monitored by real-time quantitative polymerase chain reaction as a predictor of long term response to interferon-alpha treatment, The American Journal of Gastroenterology, 2002, 97, 2, 420

    CrossRef

  135. 135
    Takahiro Yamaura, Akihiro Matsumoto, Akinori Rokuhara, Tetuya Ichijo, Ehji Tanaka, Kazuhiro Hanazaki, Shoji Kajikawa, Kendo Kiyosawa, Development of small hepatocellular carcinoma in a patient with chronic hepatitis C after 77 months of a sustained and complete response to interferon therapy, Journal of Gastroenterology and Hepatology, 2002, 17, 11
    Direct Link:
  136. 136
    Masaru Enomoto, Shuhei Nishiguchi, Motoharu Tanaka, Katsuhiko Fukuda, Tadashi Ueda, Akihiro Tamori, Daiki Habu, Tadashi Takeda, Susumu Shiomi, Yoshihisa Yano, Shuzo Otani, Dynamics of Hepatitis C Virus Monitored by Real-Time Quantitative Polymerase Chain Reaction During First 2 Weeks of IFN-βTreatment Are Predictive of Long-Term Therapeutic Response, Journal of Interferon & Cytokine Research, 2002, 22, 3, 389

    CrossRef

  137. 137
    Noboru Hirashima, Yoshihiro Matsumoto, Tomoyoshi Ohono, Yoshihide Kimura, Izumi Hasegawa, Ryuzo Ueda, Hepatic Fas Protein Expression Might Be a Predictive Factor for Hepatocellular Carcinoma Development in Patients With Chronic Hepatitis C Undergoing Interferon Therapy, Journal of Clinical Gastroenterology, 2002, 34, 3, 263

    CrossRef

  138. 138
    Hisayuki Hamada, Hiroshi Yatsuhashi, Koji Yano, Manabu Daikoku, Kokichi Arisawa, Osami Inoue, Michiaki Koga, Keisuke Nakata, Katsumi Eguchi, Michitami Yano, Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C, Cancer, 2002, 95, 2
    Direct Link:
  139. 139
    K. Hino, A. Kitase, Y. Satoh, D. Fujiwara, Y. Yamaguchi, M. Korenaga, Y. Shingai, T. Konishi, S. Yamashita, K. Uchida, K. Mori, H. Hanada, T. Kodama, K. Nukui, K. Okita, Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C, Journal of Viral Hepatitis, 2002, 9, 5
    Direct Link:
  140. 140
    MASAO OMATA, HARUHIKO YOSHIDA, YASUSHI SHIRATORI, SHUICHIRO SHIINA, Progression from chronic hepatitis to hepatocellular carcinoma: Natural course and treatments, Journal of Gastroenterology and Hepatology, 2002, 17,
    Direct Link:
  141. 141
    Jose Franco, Kia Saeian, Role of Antiviral Therapy in the Prevention of Hepatocellular Carcinoma, Journal of Vascular and Interventional Radiology, 2002, 13, 9, S191

    CrossRef

  142. 142
    Kelly A. Gebo, Geetanjali Chander, Mollie W. Jenckes, Khalil G. Ghanem, H. Franklin Herlong, Michael S. Torbenson, Samer S. El-Kamary, Eric B. Bass, Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: A systematic review, Hepatology, 2002, 36, S1
    Direct Link:
  143. 143
    Masataka Okuno, Soichi Kojima, Hisataka Moriwaki, Chemoprevention of hepatocellular carcinoma: Concept, progress and perspectives, Journal of Gastroenterology and Hepatology, 2001, 16, 12
    Direct Link:
  144. 144
    Y. Itoh, A. Morita, K. Nishioji, S. Narumi, T. Toyama, Y. Daimon, H. Nakamura, T. Kirishima, T. Okanoue, Clinical significance of elevated serum interferon- inducible protein-10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels, Journal of Viral Hepatitis, 2001, 8, 5
    Direct Link:
  145. 145
    Ryo Fukuda, Norihisa Ishimura, Sachiko Hamamoto, Makoto Moritani, Yasushi Uchida, Shunji Ishihara, Shuji Akagi, Makoto Watanabe, Yoshikazu Kinoshita, Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver, Journal of Medical Virology, 2001, 63, 3
    Direct Link:
  146. 146
    Vincent G. Bain, Effect of HCV viral dynamics on treatment design: lessons learned from HIV, The American Journal of Gastroenterology, 2001, 96, 10, 2818

    CrossRef

  147. 147
    G. V. Papatheodoridis, V. C. Papadimitropoulos, S. J. Hadziyannis, Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis, Alimentary Pharmacology & Therapeutics, 2001, 15, 5
    Direct Link:
  148. 148
    Ichiro Shimizu, Hiroshi Inoue, Mitsuyasu Yano, Hirohiko Shinomiya, Satoshi Wada, Yasuhiro Tsuji, Akemi Tsutsui, Seisuke Okamura, Hiroshi Shibata, Susumu Ito, Estrogen receptor levels and lipid peroxidation in hepatocellular carcinoma with hepatitis C virus infection, Liver, 2001, 21, 5
    Direct Link:
  149. 149
    Tekla G.J. Rossum, Arnold G. Vulto, Wim C.J. Hop, Solko W. Schalm, Glycyrrhizin-induced reduction of alt in european patients with chronic hepatitis C, The American Journal of Gastroenterology, 2001, 96, 8, 2432

    CrossRef

  150. 150
    Aijaz Ahmed, Emmet B. Keeffe, HEPATITIS C VIRUS AND LIVER TRANSPLANTATION, Clinics in Liver Disease, 2001, 5, 4, 1073

    CrossRef

  151. 151
    Shoji Kubo, Shuhei Nishiguchi, Kazuhiro Hirohashi, Hiromu Tanaka, Tadashi Tsukamoto, Taichi Shuto, Shigekazu Takemura, Takatsugu Yamamoto, Takashi Ikebe, Kenichi Wakasa, Susumu Shiomi, Hiroaki Kinoshita, Influence of Previous Interferon Therapy on Recurrence after Resection of Hepatitis C Virus-related Hepatocellular Carcinoma, Cancer Science, 2001, 92, 1
    Direct Link:
  152. 152
    Calogero Cammà, Marco Giunta, Pietro Andreone, Antonio Craxı̀, Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach, Journal of Hepatology, 2001, 34, 4, 593

    CrossRef

  153. 153
    Alvaro Aguayo, Yehuda Z. Patt, LIVER CANCER, Clinics in Liver Disease, 2001, 5, 2, 479

    CrossRef

  154. 154
    Savino Bruno, Pier Maria Battezzati, Giorgio Bellati, Aldo Manzin, Marco Maggioni, Andrea Crosignani, Mauro Borzio, Laura Solforosi, Alberto Morabito, Gaetano Ideo, Mauro Podda, Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C, Journal of Hepatology, 2001, 34, 5, 748

    CrossRef

  155. 155
    Kenji Ikeda, Satoshi Saitoh, Masahiro Kobayashi, Yoshiyuki Suzuki, Fumitaka Suzuki, Akihito Tsubota, Yasuji Arase, Naoya Murashima, Kazuaki Chayama, Hiromitsu Kumada, Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: A pilot study, Journal of Gastroenterology and Hepatology, 2001, 16, 4
    Direct Link:
  156. 156
    Yasushi Shiratori, Haruhiko Yoshida, Masao Omata, Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention, Expert Review of Anticancer Therapy, 2001, 1, 2, 277

    CrossRef

  157. 157
    Huy A. Nguyen, Samuel B. Ho, Natural history of chronic hepatitis C: Identifying a window of opportunity for intervention, Disease-a-Month, 2001, 47, 12, 593

    CrossRef

  158. 158
    Alvaro Aguayo, Yehuda Z. Patt, Nonsurgical Treatment of Hepatocellular Carcinoma, Clinics in Liver Disease, 2001, 5, 1, 175

    CrossRef

  159. 159
    Maurizio Pompili, Gian Ludovico Rapaccini, Marcello Covino, Giulia Pignataro, Eugenio Caturelli, Domenico Angelo Siena, Maria Rosaria Villani, Augusto Cedrone, Giovanni Gasbarrini, Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy, Cancer, 2001, 92, 1
    Direct Link:
  160. 160
    Hirotsugu Ikawa, Yoshitake Hayashi, Toshiaki Ninomiya, Yoshihiko Yano, Miyuki Nakaji, Hidenobu Nagano, Yasushi Seo, Yoshiko Kumon, Seitetsu Yoon, Masato Kasuga, Hiroshi Itoh, Chiho Ohbayashi, Various scoring systems evaluating histologic features of chronic hepatitis C treated with interferon, Human Pathology, 2001, 32, 9, 910

    CrossRef

  161. 161
    Yoshio Aizawa, Yuka Shibamoto, Ichiro Takagi, Mikio Zeniya, Gotaro Toda, Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C, Cancer, 2000, 89, 1
    Direct Link:
  162. 162
    Claudio Zavaglia, Aldo Airoldi, Giovambattista Pinzello, Antiviral Therapy of HBV- and HCV-induced Liver Cirrhosis, Journal of Clinical Gastroenterology, 2000, 30, 3, 234

    CrossRef

  163. 163
    Mikio Zeniya, Gotaro Toda, Case selection for interferon treatment of hepatitis C, Journal of Gastroenterology and Hepatology, 2000, 15,
    Direct Link:
  164. 164
    Kasahara, Hayashi, Mochizuki, Hiramatsu, Sasaki, Kakumu, Kiyosawa, Okita, Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy, Journal of Viral Hepatitis, 2000, 7, 5
    Direct Link:
  165. 165
    John B Wong, Gary L Davis, Stephen G Pauker, Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C, The American Journal of Medicine, 2000, 108, 5, 366

    CrossRef

  166. 166
    Hideo Tanaka, Hideaki Tsukuma, Akinori Kasahara, Norio Hayashi, Harumasa Yoshihara, Manabu Masuzawa, Tsutomu Kanda, Tohoru Kashiwagi, Atsuo Inoue, Michio Kato, Akira Oshima, Yoko Kinoshita, Takenobu Kamada, Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: A retrospective cohort study of 738 patients, International Journal of Cancer, 2000, 87, 5
    Direct Link:
  167. 167
    Massimo Colombo, Hepatocellular carcinoma in patients with HCV, Best Practice & Research Clinical Gastroenterology, 2000, 14, 2, 327

    CrossRef

  168. 168
    Masao Omata, Yasushi Shiratori, Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C, Journal of Gastroenterology and Hepatology, 2000, 15,
    Direct Link:
  169. 169
    H. Toyoda, T. Kumada, A. Tokuda, Y. Horiguchi, H. Nakano, T. Honda, S. Nakano, K. Hayashi, Y. Katano, I. Nakano, T. Hayakawa, D. Nishimura, K. Kato, K. Imada, M. Imoto, Y. Fukuda, Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C, Journal of Viral Hepatitis, 2000, 7, 6
    Direct Link:
  170. 170
    Kondili, Taliani, Tosti, De Bac, Pasquazzi, Mele, Methodological issues in papers on IFN therapy: time for reappraisal, Journal of Viral Hepatitis, 2000, 7, 3
    Direct Link:
  171. 171
    Matsumura, Moriyama, Goto, Tanaka, Okubo, Arakawa, Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C – a study of 527 patients at one establishment, Journal of Viral Hepatitis, 2000, 7, 4
    Direct Link:
  172. 172
    Ichiro Shimizu, Sho-saiko-to: Japanese herbal medicine for protection against hepatic fibrosis and carcinoma, Journal of Gastroenterology and Hepatology, 2000, 15,
    Direct Link:
  173. 173
    Hidenori Toyoda, Takashi Kumada, Satoshi Nakano, Isao Takeda, Keiichi Sugiyama, Seiki Kiriyama, Yasuhiro Sone, Yasuhiro Hisanaga, The effect of retreatment with interferon-α on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C, Cancer, 2000, 88, 1
    Direct Link:
  174. 174
    Mitsuo Shimada, Tatsuya Rikimaru, Keishi Sugimachi, Takayuki Hamatsu, Yo-ichi Yamashita, Shin-ichi Aishima, Ken-ichi Taguchi, Shinji Tanaka, Ken Shirabe, Keizo Sugimachi, The importance of hepatic resection for hepatocellular carcinoma originating from nonfibrotic liver11No competing interests declared., Journal of the American College of Surgeons, 2000, 191, 5, 531

    CrossRef

  175. 175
    Zeuzem, Treatment of chronic hepatitis C virus infection in patients with cirrhosis, Journal of Viral Hepatitis, 2000, 7, 5
    Direct Link:
  176. 176
    Mahbub H. Khan, Geoffrey C. Farrell, Karen Byth, Rita Lin, Martin Weltman, Jacob George, Dev Samarasinghe, James Kench, Songal Kaba, Evelyn Crewe, Chris Liddle, Which patients with hepatitis C develop liver complications?, Hepatology, 2000, 31, 2
    Direct Link:
  177. 177
    Kanae Yamaguchi, Katsuhisa Omagari, Hideki Kinoshita, Sumako Yoshioka, Hisashi Furusu, Fuminao Takeshima, Atsushi Nanashima, Hiroyuki Yamaguchi, Shigeru Kohno, Development of Hepatocellular Carcinoma in a Patient With Chronic Hepatitis C After 6 Years of a Sustained and Complete Response to IFN-α, Journal of Clinical Gastroenterology, 1999, 29, 2, 207

    CrossRef

  178. 178
    Katsumi Morita, Katsuaki Tanaka, Satoru Saito, Takehiko Kitamura, Takayoshi Kiba, Takando Fujii, Kazushi Numata, Hisahiko Sekihara, Expression of interferon receptor genes in the liver as a predictor of interferon response in patients with chronic hepatitis C, Journal of Medical Virology, 1999, 58, 4
    Direct Link:
  179. 179
    Massimo Colombo, Hepatitis C virus and hepatocellular carcinoma, Best Practice & Research Clinical Gastroenterology, 1999, 13, 4, 519

    CrossRef

  180. 180
    Hugo R Rosen, David R Gretch, Hepatitis C virus: current understanding and prospects for future therapies, Molecular Medicine Today, 1999, 5, 9, 393

    CrossRef

  181. 181
    Daniel F Schafer, Michael F Sorrell, Hepatocellular carcinoma, The Lancet, 1999, 353, 9160, 1253

    CrossRef

  182. 182
    Graeme A. Macdonald, Hepatocellular carcinoma, Current Opinion in Gastroenterology, 1999, 15, 3, 253

    CrossRef

  183. 183
    Geoffrey C Farrell, Hepatocellular carcinoma after sustained response to interferon in non-cirrhotic hepatitis C: Flaws in the cure, or a clue to the flaws?, Journal of Gastroenterology and Hepatology, 1999, 14, 9
    Direct Link:
  184. 184
    Hirohisa Yano, Akihiro Iemura, Makoto Haramaki, Sachiko Ogasawara, Akiko Takayama, Jun Akiba, Masamichi Kojiro, Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines, Hepatology, 1999, 29, 6
    Direct Link:
  185. 185
    Takeshi Okanoue, Yoshito Itoh, Masahito Minami, Shinichi Sakamoto, Kohichiro Yasui, Masafumi Sakamoto, Kenichi Nishioji, Yoshiki Murakami, Kei Kashima, Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients, Journal of Hepatology, 1999, 30, 4, 653

    CrossRef

  186. 186
    R. A. Willson, S. H. Fischer, H. D. Ochs, Long-Term Interferon Alpha Maintenance Therapy for Chronic Hepatitis C Infection in a Patient With Common Variable Immune Deficiency, Journal of Clinical Gastroenterology, 1999, 29, 2, 203

    CrossRef

  187. 187
    Shi-Ming Lin, I-Shyan Sheen, Rong-Nan Chien, Chia-Ming Chu, Yun-Fan Liaw, Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection, Hepatology, 1999, 29, 3
    Direct Link:
  188. 188
    Joanne Imperial, Natural history of chronic hepatitis B and C, Journal of Gastroenterology and Hepatology, 1999, 14, 5s
    Direct Link:
  189. 189
    Solko W. Schalm, Johannes T. Brouwer, Frank C. Bekkering, Tekla G.J. van Rossum, New treatment strategies in non-responder patients with chronic hepatitis C, Journal of Hepatology, 1999, 31, 184

    CrossRef

  190. 190
    Kentaro Yoshioka, Motoyoshi Yano, Atsuhiko Kusakabe, Hideo Hirofuji, Akihiko Fuji, Junsuke Kuriki, Motohiro Arao, Kenichi Murase, Ryuichi Kidokoro, Shinichi Kakumu, Randomized controlled trial of lymphoblastoid interferon alpha for chronic hepatitis C (comparison of 9-MU and 6-MU doses), The American Journal of Gastroenterology, 1999, 94, 1, 164

    CrossRef

  191. 191
    U. Dutta, K. Byth, J. Kench, M. H. Khan, S. A. Coverdale, M. Weltman, R. Lin, C. Liddle, G. C. Farrell, Risk factors for development of hepatocellular carcinoma among Australians with hepatitis C: a case-control study, Australian and New Zealand Journal of Medicine, 1999, 29, 3
    Direct Link:
  192. 192
    Masaaki Wada, Takashi Miyoshi, Miki Fujimoto, Hiromasa Kamimoto, Akira Kinugasa, Koji Sawada, Takashi Shimoyama, Serum Levels of Thyroid-Stimulating Hormone Receptor Antibodies during IFN-alpha2a Treatment of Chronic Hepatitis C, Journal of Interferon & Cytokine Research, 1999, 19, 1, 85

    CrossRef

  193. 193
    S. Sherlock, The hepatic flaviviridae: summary, Journal of Viral Hepatitis, 1999, 6,
    Direct Link:
  194. 194
    Ke-Qin Hu, Myron J. Tong, The long-term outcomes of patients with compensated hepatitis C virus–related cirrhosis and history of parenteral exposure in the united states, Hepatology, 1999, 29, 4
    Direct Link:
  195. 195
    C. Silvain, Traitements antiviraux de l’infection par le virus de l’hépatite C, La Revue de Médecine Interne, 1999, 20, 331s

    CrossRef

  196. 196
    Dominique-Charles Valla, Michele Chevallier, Patrick Marcellin, Jean-Louis Payen, Christian Trepo, Marianne Fonck, Marc Bourliere, Evelyne Boucher, Jean-Philippe Miguet, David Parlier, Catherine Lemonnier, Pierre Opolon, Treatment of hepatitis C virus–related cirrhosis: A randomized, controlled trial of interferon alfa-2b versus no treatment, Hepatology, 1999, 29, 6
    Direct Link:
  197. 197
    F. Bonino, f. Oliveri, P. Colombatto, B. Coco, D. Mura, G. Realdi, M.R. Brunetto, Treatment of patients with chronic hepatitis C and cirrhosis, Journal of Hepatology, 1999, 31, 197

    CrossRef

  198. 198
    Aijaz Ahmed, Emmet Keeffe, Treatment strategies for chronic hepatitis C: Update since the 1997 National Institutes of Health Consensus Development Conference, Journal of Gastroenterology and Hepatology, 1999, 14, 5s
    Direct Link:
  199. 199
    Marina Berenguer, Teresa L. Wright, TREATMENT STRATEGIES FOR RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION, Clinics in Liver Disease, 1999, 3, 4, 883

    CrossRef

  200. 200
    Arie Regev, Eugene R. Schiff, Viral hepatitis, Current Opinion in Gastroenterology, 1999, 15, 3, 234

    CrossRef

  201. 201
    Thierry Poynard, Pierre Opolon, Hepatitis C: Somber views of natural history and optimistic views of interferon treatment?, Hepatology, 1998, 27, 5
    Direct Link:
Get PDF (112K)